relatlimab+nivolumab

Phase 3Monoclonal antibody

Bristol-Myers Squibb

relatlimab+nivolumab is one of 64 small molecule programs targeting Metastatic Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

MelanomaRecruiting

Metastatic MelanomaPhase 3

Active, not recruiting

MelanomaPhase 3

Recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

31 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 3

Imjudo

AstraZeneca

Phase 3

2 4

ABP 234

Amgen

Phase 3

1 5

GSK 257049

GSK

Phase 3

1 6

Tyrosinase Peptide

EEastern Cooperative Oncology Group

Phase 3

15 7

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 8

relatlimab+nivolumab

Bristol-Myers Squibb

Phase 3

2 9

Intron a

Merck & Co.

Preclinical

4 10

Opdualag

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Melanoma

NCT06101134

Q3 2033

Phase 3Recruiting

Melanoma

NCT06246916

Clinical

Trials by Indication[1]

Melanoma2 trials

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT06101134·100 enrolled

A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06246916·560 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for relatlimab+nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — relatlimab+nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for relatlimab+nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

relatlimab+nivolumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2033

Trials by Indication[1]

Melanoma2 trials

References

Drug Info

Quick Facts

Related News